Work

Phase 1 LITESPARK-001 (MK-6482-001) study of belzutifan in advanced solid tumors: Update of the clear cell renal cell carcinoma (ccRCC) cohort with more than 3 years of total follow-up.

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.16_suppl.4509

Authors: Eric Jonasch, Todd Michael Bauer, Kyriakos P. Papadopoulos, Elizabeth R. Plimack, Jaime R. Merchan, David F. McDermott, M. Dror Michaelson, Leonard Joseph Appleman, Ananya Roy, Yanfang Liu, Rodolfo F. Perini, Toni K. Choueiri

Institutions: The University of Texas MD Anderson Cancer Center, Sarah Cannon, Tennessee Oncology, South Texas Accelerated Research Therapeutics, Fox Chase Cancer Center, University of Miami Health System, Beth Israel Deaconess Medical Center, Massachusetts General Hospital, University of Pittsburgh Medical Center, Merck & Co., Inc., Rahway, NJ, USA (United States), Dana-Farber Cancer Institute

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4286298689

Cites:

Cited by: 19

Related to: 10